Cargando…

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a variable clinical course. Novel biomarkers discovered over the past 20 years have revolutionized the way clinicians approach prognostication and treatment especially in the chemotherapy-free era. Herein, we review the best establis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Jared A., Bomben, Riccardo, Pozzo, Federico, Tissino, Erika, Härzschel, Andrea, Hartmann, Tanja Nicole, Zucchetto, Antonella, Gattei, Valter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226446/ https://www.ncbi.nlm.nih.gov/pubmed/32272636 http://dx.doi.org/10.3390/cancers12040894

Ejemplares similares

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond
por: Pozzo, Federico, et al.
Publicado: (2022)

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
por: Vendramini, Elena, et al.
Publicado: (2022)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects
por: Härzschel, Andrea, et al.
Publicado: (2020)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
por: Szenes, Eva, et al.
Publicado: (2020)

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
por: Pozzo, Federico, et al.
Publicado: (2020)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
por: Tissino, Erika, et al.
Publicado: (2018)

S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY
por: Tissino, Erika, et al.
Publicado: (2023)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
por: Zucchetto, Antonella, et al.
Publicado: (2006)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009)

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms
por: Hutterer, Evelyn, et al.
Publicado: (2015)

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
por: Vendramini, Elena, et al.
Publicado: (2019)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
por: Rossi, Francesca M, et al.
Publicado: (2010)

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21
por: Ganghammer, Sylvia, et al.
Publicado: (2015)

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015)

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
por: Tsagiopoulou, Maria, et al.
Publicado: (2019)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany
por: Kajüter, Hiltraud, et al.
Publicado: (2021)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
por: Vit, Filippo, et al.
Publicado: (2023)

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
por: Cohen, Jared A., et al.
Publicado: (2020)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy
por: Porrazzo, Marika, et al.
Publicado: (2020)

The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential
por: Dal Bo, Michele, et al.
Publicado: (2015)

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes
Publicado: (1981)

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
por: Huang, Qing, et al.
Publicado: (2022)

A case of SRSF2 mutation in chronic lymphocytic leukemia
por: Garza, Eduardo, et al.
Publicado: (2016)

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?
por: Cuneo, Antonio, et al.
Publicado: (2019)

A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
por: Kay, Neil E., et al.
Publicado: (2016)

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
por: Herbst, Sophie A., et al.
Publicado: (2022)

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
por: Wang, Jiguang, et al.
Publicado: (2014)

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
por: González-Rincón, Julia, et al.
Publicado: (2021)

Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
por: Chen, Mo, et al.
Publicado: (2022)

Rac GTPases in Hematological Malignancies
por: Durand-Onaylı, Valerie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2le2t62ctp8a39500eqp7sfads